FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387080083> ?p ?o ?g. }

• W4387080083 abstract "Central nervous system (CNS) WHO grade 2 low-grade glioma (LGG) patients are at high risk for recurrence and with unfavorable long-term prognosis due to the treatment resistance and malignant transformation to high-grade glioma. Considering the relatively intact systemic immunity and slow-growing nature, immunotherapy may offer an effective treatment option for LGG patients.We conducted a prospective, randomized pilot study to evaluate the safety and immunological response of the multi-peptide IMA950 vaccine with agonistic anti-CD27 antibody, varlilumab, in CNS WHO grade 2 LGG patients. Patients were randomized to receive combination therapy with IMA950+poly-ICLC and varlilumab (Arm 1) or IMA950+poly-ICLC (Arm 2) before surgery, followed by adjuvant vaccines.A total of 14 eligible patients were enrolled in the study. Four patients received pre-surgery vaccines but were excluded from post-surgery vaccines due to the high-grade diagnosis of the resected tumor. No regimen-limiting toxicity was observed. All patients demonstrated a significant increase of anti-IMA950 CD8 + T-cell response post-vaccine in the peripheral blood, but no IMA950-reactive CD8 + T-cells were detected in the resected tumor. Mass cytometry analyses revealed that adding varlilumab promoted T helper type 1 effector memory CD4 + and effector memory CD8 + T-cell differentiation in the PBMC but not in the tumor microenvironment.The combinational immunotherapy, including varlilumab, was well-tolerated and induced vaccine-reactive T-cell expansion in the peripheral blood but without a detectable response in the tumor. Further developments of strategies to overcome the blood-tumor barrier are warranted to improve the efficacy of immunotherapy for LGG patients." @default.
• W4387080083 created "2023-09-28" @default.
• W4387080083 creator A5006262715 @default.
• W4387080083 creator A5010550108 @default.
• W4387080083 creator A5013092869 @default.
• W4387080083 creator A5014709556 @default.
• W4387080083 creator A5018563666 @default.
• W4387080083 creator A5019140507 @default.
• W4387080083 creator A5020755903 @default.
• W4387080083 creator A5033073004 @default.
• W4387080083 creator A5038354675 @default.
• W4387080083 creator A5045031619 @default.
• W4387080083 creator A5048998314 @default.
• W4387080083 creator A5051168746 @default.
• W4387080083 creator A5052248018 @default.
• W4387080083 creator A5052983963 @default.
• W4387080083 creator A5058793243 @default.
• W4387080083 creator A5065465191 @default.
• W4387080083 creator A5071216293 @default.
• W4387080083 creator A5073708381 @default.
• W4387080083 creator A5074051971 @default.
• W4387080083 creator A5076038018 @default.
• W4387080083 creator A5083210287 @default.
• W4387080083 creator A5083711110 @default.
• W4387080083 creator A5090305344 @default.
• W4387080083 creator A5091257992 @default.
• W4387080083 creator A5091554806 @default.
• W4387080083 creator A5091736003 @default.
• W4387080083 date "2023-09-27" @default.
• W4387080083 modified "2023-10-03" @default.
• W4387080083 title "A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas" @default.
• W4387080083 doi "https://doi.org/10.1093/neuonc/noad185" @default.
• W4387080083 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37758193" @default.
• W4387080083 hasPublicationYear "2023" @default.
• W4387080083 type Work @default.
• W4387080083 citedByCount "0" @default.
• W4387080083 crossrefType "journal-article" @default.
• W4387080083 hasAuthorship W4387080083A5006262715 @default.
• W4387080083 hasAuthorship W4387080083A5010550108 @default.
• W4387080083 hasAuthorship W4387080083A5013092869 @default.
• W4387080083 hasAuthorship W4387080083A5014709556 @default.
• W4387080083 hasAuthorship W4387080083A5018563666 @default.
• W4387080083 hasAuthorship W4387080083A5019140507 @default.
• W4387080083 hasAuthorship W4387080083A5020755903 @default.
• W4387080083 hasAuthorship W4387080083A5033073004 @default.
• W4387080083 hasAuthorship W4387080083A5038354675 @default.
• W4387080083 hasAuthorship W4387080083A5045031619 @default.
• W4387080083 hasAuthorship W4387080083A5048998314 @default.
• W4387080083 hasAuthorship W4387080083A5051168746 @default.
• W4387080083 hasAuthorship W4387080083A5052248018 @default.
• W4387080083 hasAuthorship W4387080083A5052983963 @default.
• W4387080083 hasAuthorship W4387080083A5058793243 @default.
• W4387080083 hasAuthorship W4387080083A5065465191 @default.
• W4387080083 hasAuthorship W4387080083A5071216293 @default.
• W4387080083 hasAuthorship W4387080083A5073708381 @default.
• W4387080083 hasAuthorship W4387080083A5074051971 @default.
• W4387080083 hasAuthorship W4387080083A5076038018 @default.
• W4387080083 hasAuthorship W4387080083A5083210287 @default.
• W4387080083 hasAuthorship W4387080083A5083711110 @default.
• W4387080083 hasAuthorship W4387080083A5090305344 @default.
• W4387080083 hasAuthorship W4387080083A5091257992 @default.
• W4387080083 hasAuthorship W4387080083A5091554806 @default.
• W4387080083 hasAuthorship W4387080083A5091736003 @default.
• W4387080083 hasConcept C126322002 @default.
• W4387080083 hasConcept C143998085 @default.
• W4387080083 hasConcept C167672396 @default.
• W4387080083 hasConcept C203014093 @default.
• W4387080083 hasConcept C2776090121 @default.
• W4387080083 hasConcept C2777701055 @default.
• W4387080083 hasConcept C2777863537 @default.
• W4387080083 hasConcept C2778227246 @default.
• W4387080083 hasConcept C2781413609 @default.
• W4387080083 hasConcept C502942594 @default.
• W4387080083 hasConcept C71924100 @default.
• W4387080083 hasConcept C8891405 @default.
• W4387080083 hasConceptScore W4387080083C126322002 @default.
• W4387080083 hasConceptScore W4387080083C143998085 @default.
• W4387080083 hasConceptScore W4387080083C167672396 @default.
• W4387080083 hasConceptScore W4387080083C203014093 @default.
• W4387080083 hasConceptScore W4387080083C2776090121 @default.
• W4387080083 hasConceptScore W4387080083C2777701055 @default.
• W4387080083 hasConceptScore W4387080083C2777863537 @default.
• W4387080083 hasConceptScore W4387080083C2778227246 @default.
• W4387080083 hasConceptScore W4387080083C2781413609 @default.
• W4387080083 hasConceptScore W4387080083C502942594 @default.
• W4387080083 hasConceptScore W4387080083C71924100 @default.
• W4387080083 hasConceptScore W4387080083C8891405 @default.
• W4387080083 hasLocation W43870800831 @default.
• W4387080083 hasLocation W43870800832 @default.
• W4387080083 hasOpenAccess W4387080083 @default.
• W4387080083 hasPrimaryLocation W43870800831 @default.
• W4387080083 hasRelatedWork W1986962886 @default.
• W4387080083 hasRelatedWork W1996150995 @default.
• W4387080083 hasRelatedWork W2090324576 @default.
• W4387080083 hasRelatedWork W2350488082 @default.
• W4387080083 hasRelatedWork W2387430262 @default.
• W4387080083 hasRelatedWork W2652729657 @default.
• W4387080083 hasRelatedWork W3167775801 @default.
• W4387080083 hasRelatedWork W4210825082 @default.
• W4387080083 hasRelatedWork W4385616388 @default.

• next